Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


METHOD OF USING A TRANSGENIC NONHUMAN ANIMAL TO MANUFACTURE A PROTEIN WHICH IS THEN TO BE ISOLATED OR EXTRACTED

Subclass of:

800 - Multicellular living organisms and unmodified parts thereof and related processes

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
800004000METHOD OF USING A TRANSGENIC NONHUMAN ANIMAL TO MANUFACTURE A PROTEIN WHICH IS THEN TO BE ISOLATED OR EXTRACTED89
20110179503PROTEIN PRODUCTION IN A HOST - Recombinant DNA constructs that provide for expression of desired target proteins as protein bodies in various host cells, tissues, and organisms are disclosed. Such recombinant DNA constructs contain a heterologous polynucleotide comprising an ER luminal folding chaperone interacting domain (CID), a sequence that codes for a trans-membrane domain (TMD); and a sequence that codes for a protein-protein interaction domain (PPID) that are operably linked to a sequence encoding the desired target protein. Proteins obtained from the constructs, host cells containing the constructs, and methods for obtaining desired target proteins encoded by the constructs are also disclosed.07-21-2011
20090193529Method for Generating Antibodies - Methods for generating antibodies in rodents are disclosed. The antibodies are useful as therapeutic agents, diagnostic agents or research reagents.07-30-2009
20110203010INSECT-DERIVED PROMOTERS FOR FOREIGN PROTEINS EXPRESSION IN INSECT CELLS - Insect-derived promoters for foreign proteins expression in insect cells. Regulatory polynucleotide sequences which drive the expression of major insect proteins (hexamerins) at specific evolution stages of larva have been isolated from insects (08-18-2011
20110203009METHOD FOR PRODUCING GLYCOPROTEIN CHARACTERIZED BY SUGAR CHAIN STRUCTURE BY USING SILKWORM - It is an object of the present invention to investigate what kinds of structures a sugar chain has by performing a sugar chain structural analysis of a glycoprotein produced in a transgenic silkworm. For the sugar chain of the glycoprotein produced in the transgenic silkworm, a glycoprotein having a sugar chain structure in which fucose is not linked to N-acetylglucosamine at a reducing terminal of the sugar chain is obtained. In addition, a glycoprotein having an almost completely humanized sugar chain structure is obtained by further integrating GalT gene into this transgenic silkworm.08-18-2011
20090307786Methods for producing a protein using an avian lysozyme promoter - The invention includes methods of producing proteins in transgenic avians containing nucleic acids in their genome which contain an exogenous lysozyme gene expression controlling nucleotide sequence which typically is linked to a polynucleotide encoding a heterologous polypeptide.12-10-2009
20120117669HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENOMICE - Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.05-10-2012
20090100533Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host sytems - The present invention relates to a novel method for preparing gamma-carboxylated poly-peptides, including coagulation Factors VII, IX, X and Protein C. The present invention also relates to novel host cells and recombinant vectors to be used in this improved method for preparing gamma-carboxylated polypeptides.04-16-2009
20080301823Polynucleotide for Producing Recombinant Protein in Silkworm - As novel means for causing any recombinant protein produced by the silkworm middle silk gland to be secreted in cocoons and easily extracting the recombinant protein from the cocoons without modification of the conformation of the protein, there is provided a polynucleotide that in an expression cassette for expression of a recombinant protein by the silkworm middle silk gland, is functionally linked to a recombinant protein structure gene, which polynucleotide is one composed of a polynucleotide constructing the promoter regions of sericin 1 or sericin 2 gene and, functionally linked thereto, a polynucleotide constructing the homologous regions of baculovirus.12-04-2008
20090288178INSECT CELL LINE FOR PRODUCTION OF RECOMBINANT GLYCOPROTEINS WITH SULFATED COMPLEX N-GLYCANS - A transgenic insect cell line for production of recombinant glycoproteins possessing sulfated, complex N-glycans is provided.11-19-2009
20100071080ANTIBODIES TO SULFATED CARBOHYDRATES - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to chondroitin sulfate, particularly CS-A, CS-C and CS-E tetrasaccharides. The present invention also relates to methods of making anti-CS antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment.03-18-2010
20100083389Production of heterologous protein in the avian oviduct - The invention includes methods of making transgenic avians by introducing a nucleic acid sequence into the genome of an avian embryo wherein the nucleic acid sequence comprises a nucleotide sequence encoding a heterologous protein, developing the avian embryo to hatch, developing the hatched chick to sexual maturity and obtaining offspring from the sexually mature hatched chick which produce egg white containing the heterologous protein.04-01-2010
20110209228METHOD OF TREATMENT USING ANTIMICROBIAL COMPOSITION - The present invention provides peptides and analogs and derivatives thereof having antimicrobial activity at least against 08-25-2011
20080235813Gene regulation in transgenic animals using a transposon-based vector - Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.09-25-2008
20100212030USE OF N-TERMINAL AND C-TERMINAL PROTEOMICS TECHNOLOGY TO ENHANCE PROTEIN THERAPEUTICS AND DIAGNOSTICS - The present invention provides a novel method for stabilizing proteins, by first identifying the proteolytic sites using N- or C-terminal technology, followed by modification of said sites in order to create stabilized proteins, no longer subject to proteolytic cleavage. the method of the invention immediately provides the user with the exact amino acid position of the proteolytic cleavage site in the protein(s) of interest, even in a complex protein sample. This makes the specific modification of such a site much easier and increases the expectation of success as compared to the amount of effort needed, even in a complex protein sample.08-19-2010
20090199306Fucosyl transferase gene - A DNA molecule is provided which comprises a sequence according to SEQ ID NO: 1 having an open reading frame from base pair 211 to base pair 1740 or having at least 50% homology to the above-indicated sequence, or hybridizing with the above-indicated sequence under stringent conditions, or comprising a sequence which has degenerated to the above-indicated DNA sequence because of the genetic code, the sequence coding for a plant protein having fucosyltransferase activity or being complementary thereto.08-06-2009
20090210951Avian transgenesis using an ovalbumin nucleotide sequence - The invention includes delivering to an avian a nucleic acid molecule which includes nucleotide sequence of an ovalbumin gene expression controlling region and a heterologous coding sequence operably linked to the gene expression controlling region wherein the heterologous coding sequence is expressed in a cell of the avian.08-20-2009
20100162417METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGEN - The present invention relates to methods for increasing the diversity of monoclonal antibodies produced against an antigen. The methods of the invention utilize immunization of a murine host defective in one or more enzymes involved in a post-translational modification of a polypeptide or a modification of a lipid, wherein said modification is exposed on a cell surface. The invention also relates to monoclonal antibodies produced by these methods and which are not produced when a normal mouse is immunized with the same antigen. The invention further relates to compositions comprising these monoclonal antibodies, as well as to such monoclonal antibodies bound or conjugated to a toxin, a detectable marker or to a solid support.06-24-2010
20100186099Production of Human Glycosylated Proteins in Silk Worm - A transgenic silkworm system for recombinant glycoprotein production is provided.07-22-2010
20100235929Compositions and Methods for Producing Antibodies Having Human Idiotypes in Transgenic Birds - The invention relates to compositions and methods for producing antibodies having human idiotypes in non-human animals.09-16-2010
20100205678OOCYTE SPINDLE-ASSOCIATED FACTORS IMPROVE SOMATIC CELL CLONING - The invention pertains to the discovery that the presence of oocyte spindle associated factors in an enucleated oocyte improves oocyte quality and subsequently nuclear transfer. In particular, it was discovered that maintaining oocyte spindle factors in the oocyte after enucleation improves oocyte quality for use in nuclear transfer methodology.08-12-2010
20100333218TRANSGENIC PROTEINS FROM MULTI-GENE SYSTEMS, METHODS, COMPOSITIONS, USES AND THE LIKE RELATING THERETO - A non-human transgenic mammalian animal, as described above, contains one or more exogenous double stranded DNA sequence(s) stably integrated into the genome of the animal, which comprises trans-acting regulatory units controlling expression of DNA sequences encoding proteins to be secreted into the milk of transgenic mammals. The DNA sequence of the trans-regulatory gene encodes transcriptional activating proteins, which are not secreted but made in a temporally controlled and mammary tissue specific manner. The DNA sequence containing the protein to be secreted in the milk is constructed on a separate gene sequence under the regulation of a minimal promoter and a trans-activation binding domain. The transgenic mammals are preferably pigs, cows, sheep, goats and rabbits. A related composition and method for making transgenic proteins which require specialized propeptides for proper post-translational processing is also described.12-30-2010
20100333219Methods of protein production using ovomucoid regulatory regions - Methods of producing protein using a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences.12-30-2010
20100146647Antibody producing non-human mammals - Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.06-10-2010
20110093961MOUSE LAMBDA LIGHT CHAIN LOCUS - The present invention provides in a first aspect a mouse in which the λ (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse λ light chain locus was functional silenced by deletion of gene segments coding for the λ light chain locus. In a further aspect, a mouse containing functionally silenced λ and κ (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.04-21-2011
20090217392ANTI- INTEGRIN ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.08-27-2009
20110035817SIVA 3, ITS PREPARATION AND USE - The present invention relates to a splice variant of SIVA, SIVA3, and to its use.02-10-2011
20110258710Methods of Modifying Eukaryotic Cells - A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.10-20-2011
20100122358H-Chain-only antibodies - The invention relates to mice having functionally silenced endogenous lambda (λ) and kappa (κ) L-chain loci, comprising antibody-producing cells in which the C05-13-2010
20100077494Ungulates with Genetically Modified Immune Systems - The present invention provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which lack expression of functional endogenous immunoglobulin loci. The present invention also provides ungulate animals, tissue and organs as well as cells and cell lines derived from such animals, tissue and organs, which express xenogenous, such as human, immunoglobulin loci. The present invention further provides ungulate, such as porcine genomic DNA sequence of porcine heavy and light chain immunogobulins. Such animals, tissues, organs and cells can be used in research and medical therapy. In addition, methods are provided to prepare such animals, organs, tissues, and cells.03-25-2010
20090133134METHOD AND COMPOSITION FOR GENETICALLY MODIFYING NON-HUMAN CELLS AND ANIMALS - The present invention is directed to a vector and its use to generate genetically modified animals and cells. One aspect of this invention involves a vector that comprises a sperm cell and one or more polynucleotide molecules bound to a sperm cell through one or more sperm antibody linker. The sperm cell can be any animal sperm cell, preferably non-human animal such as a mouse, pig, sheep, goat, or chicken. In one preferred embodiment of this invention, the one or more polynucleotide molecules encode for a gene product that confers desired characteristics in the cells or the animals. In another preferred embodiment of this invention, the genetically modified cells are able to produce desired therapeutic proteins. The association of the sperm, linker, and the one or more polynucleotide can also occur in vitro or in vivo. In another embodiment, the genetically modified cells are transgenic chicken eggs in which one or more desired recombinant protein is expressed.05-21-2009
20120047585HCO32 AND HCO27 AND RELATED EXAMPLES - The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.02-23-2012
20120117670HUMANIZED AXL ANTIBODIES - The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.05-10-2012
20090178147Glycosylation in avians - Transgenic avians which produce proteins in their oviduct tissue having modified oligosaccharide structures and methods of making such avians are disclosed herein. The invention also includes the modified proteins produced in the transgenic birds.07-09-2009
20100287629Transgenic Non-Human Animals For Producing Chimeric Antibodies - The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.11-11-2010
20110191866METHODS OF MAKING MONOCLONAL ANTIBODIES USING FUSION-PEPTIDE EPITOPE ADOPTIVE TRANSFER (F-PEAT) TECHNOLOGY - Disclosed are compositions and methods for related to monoclonal antibodies specific for single amino acid variation in an antigen.08-04-2011
20100281549Transgenic Production In Saliva - The invention relates to the production of proteins and other substances of interest in saliva of transgenic animals, particularly in mammals that produce large quantities of saliva, particularly monogastric ruminants, and ovine, caprine and bovine mammals. Preferred embodiments of the invention relate in particular to the production of foreign and modified proteins in the transgenic saliva of these animals, including particularly human fibrinogen, human prothrombin and human thrombin, among others. The invention relates as well to methods, devices, genetic constructs and to transgenic constructs for making the proteins and other substances of interest, to novel saliva and saliva-derived compositions, novel products produced from the saliva, and to uses of the saliva, saliva-derived compositions and novel products.11-04-2010
20110004949IMMUNOGLOBULIN 1 - The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single chain camelid VHH antibodies in a mammal which undergo the process of class-switching and affinity maturation found within antibody producing B cells. Single chain antibodies generated using the method of the present invention and the uses thereof are also described.01-06-2011
20110004948IMMUNOGLOBULIN 2 - The present invention relates to a method for the generation of single chain immunoglobulins in a mammal. In particular, the present invention relates to a method for the generation of single chain camelid VHH antibodies in a mammal which undergo the process of class-switching and affinity maturation found within antibody producing B cells. Single chain antibodies generated using the method of the present invention and the uses thereof are also described.01-06-2011
20120272344TRANSGENIC ANIMALS EXPRESSING CHIMERIC ANTIBODIES FOR USE IN PREPARING HUMAN ANTIBODIES - The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.10-25-2012
20110162093METHODS FOR PRODUCING ANTIBODIES - [Problems to be Solved] The present invention provides methods for producing antibodies and antibody-producing cells.06-30-2011
20130024956ANTIBODIES TO CD40 - The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.01-24-2013
20080222739Therapeutic Clostridium difficile antibody compositions09-11-2008
20130145484ANTIBODY PRODUCING NON-HUMAN MAMMALS - Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.06-06-2013
20110239313METHOD FOR PRODUCTION OF TRACP5b - Silkworms which have (i) a DNA encoding a transcriptional regulator operably linked downstream of a promoter of a DNA encoding a protein specifically expressed in the silk gland and (ii) a DNA encoding TRACP5 operably linked downstream of a target promoter of the transcriptional regulator were produced. The result showed that active TRACP5b was produced from the silkworms. This means that TRACP5 produced from the silk gland of the silkworms undergoes processing in the silk gland that is similar to the processing taking place at bone resorption sites.09-29-2011
20110296541PRODUCTION OF PROTEINS IN EGGS - Methods for preparing recombinant proteins, such as antibodies, in eggs are described. The method offers advantages over existing systems for preparing recombinant proteins including high yield, low cost and compatibility with animal protection regulations. In addition, since eggs are edible food sources the recombinant protein does not have to be isolated from the egg.12-01-2011
20110314563ANTIBODY PRODUCTION - A non-human mammal containing an endogenous lambda light chain gene locus, an endogenous kappa light chain gene locus and an endogenous heavy chain gene locus, each of which can re-arrange so that immunoglobulin heavy and light chain genes are formed and expressed in B-cells following antigen challenge but said loci have been mutated so that the ability to form functional immunoglobulin tetramers comprising re-arranged heavy and light chains produced from said mutated loci has been substantially reduced or eliminated.12-22-2011
20110314562Insect Infection Method for Production of Proteins - The present invention provides an insect infection method for use in the production of a protein with a baculovirus expression vector in the insect, the method comprising the steps of: 12-22-2011
20120096569ANTI-IL-6 ANTIBODIES,COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.04-19-2012
20130212717METHOD FOR PRODUCING PENTAMERIC CRP, PENTAMERIC CRP-PRODUCING TRANSGENIC SILKWORM AND METHOD FOR CONSTRUCTING SAME, DNA ENCODING CANINE MONOMERIC CRP AND EXPRESSION VECTOR CONTAINING THE DNA - Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.08-15-2013
20130212718CHIMERIC SPIDER SILK AND USES THEREOF - Transgenic silkworms comprising at least one nucleic acid encoding a chimeric silk polypeptide comprising one or more spider silk elasticity and strength motifs are disclosed. Expression cassettes comprising nucleic acids encoding a variety of chimeric spider silk polypeptides (Spider 2, Spider 4, Spider 6, Spider 8) are also disclosed. A piggyBac vector system is used to incorporate nucleic acids encoding chimeric spider silk polypeptides into the mutant silkworms to generate stable transgenic silkworms. Chimeric silk fibers having improved tensile strength and elasticity characteristics compared to native silkworm silk fibers are also provided. The transgenic silkworms greatly facilitate the commercial production of chimeric silk fibers suitable for use in a wide variety of medical and industrial applications.08-15-2013
800005000 The protein is isolated or extracted from blood or serum 28
20090158449TRANSGENIC AVIAN WHICH HAS FOREIGN GENE CONTAINING SEQUENCE ENCODING FELINE-DERIVED PROTEIN AND METHOD FOR PRODUCTION THEREOF - The present invention has for its object to provide a transgenic bird with a foreign gene containing a feline-derived protein-encoding sequence as transferred therein, and a method of producing the same. The present invention provides a method of producing a feline-derived protein by using a transgenic bird with a method which comprises infecting an avian embryo with a replication defective retrovirus vector containing a foreign gene by microinjection thereof into the early heart or blood vessel formed in the embryo and allowing the embryo to hatch.06-18-2009
20080216181Novel Alcohol Dehydrogenases - The invention relates to novel polypeptides which have the biological activity of an NAD- or NADP-dependent alcohol dehydrogenase. The invention furthermore relates to nucleic acids encoding said polypeptides, to non-human hosts or host cells and to reaction systems which may be used for preparing desired products. The polypeptides of the invention are preferably used in the preparation, starting from aldehydes or ketones, of primary and enantiomerically pure secondary alcohol's which may serve as intermediates for medicaments. Alternatively, the polypeptides of the invention may also be employed in the reverse reaction, i.e. the oxidation of alcohol's with the formation of aldehydes or ketones.09-04-2008
20090064351TRANSGENIC BIRD PRODUCING ERYTHROPOIETIN AND METHOD OF CONSTRUCTING THE SAME - The present invention has its object to provide a transgenic bird producing erythropoietin at high concentration levels as well as a method for constructing the same. The present invention provides a G0 transgenic chimera bird as obtained by incubating a fertilized avian egg, infecting the early embryo formed after egg laying, except for the blastoderm stage immediately following egg laying, with a replication-deficient retroviral vector containing a foreign erythropoietin gene and allowing the embryo to hatch.03-05-2009
800006000 The protein is an immunoglobulin 25
20100333220HUMAN TISSUE FACTOR-PRODUCING KNOCK-IN NON-HUMAN ANIMAL - A non-human animal that produces human tissue factor (TF) without substantially producing non-human animal tissue factor, said animal having a genome in which cDNA encoding human TF has been inserted upstream of the translation initiation codon for the non-human animal genomic TF gene.12-30-2010
20090307787GENERATION OF HEAVY-CHAIN ONLY ANTIBODIES IN TRANSGENIC ANIMALS - The present invention relates to a method for the generation of V12-10-2009
20090094704Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84 - Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH.04-09-2009
20090271880BINDING MOLECULES - The present invention relates to methods for engineering VH domains to improve their solubility and stability. The invention provides for the incorporation of defined amino acid substitutions based on 3-D structural information into the V segments of a heavy chain locus, expressing the locus in a non-human mammal and selecting soluble VH domains. Further stabilising or solubilising mutations maybe introduced as a result affinity maturation during B-cell maturation in vivo.10-29-2009
20090222935Transgenic animals and uses thereof - In general, the invention features genetically modified non-human mammals (e.g., bovines and other ungulates), and methods of making these mammals. In particular, the invention features transgenic ungulates having reduced levels of endogenous IgM heavy chain and/or prion protein.09-03-2009
20080282363METHODS FOR PRODUCING HUMAN ANTIBODIES IN SCID MICE - An improved method for producing human antibodies in SCID mice is provided. The improvement includes the use of dendritic cells pulsed with antigen-antibody complexes and antigen-antibody complexes as immunizing agents.11-13-2008
20120198575METHODS AND COMPOSITIONS FOR DETERMINING THE PURITY OF CHEMICALLY SYNTHESIZED NUCLEIC ACIDS - This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.08-02-2012
20110145937Mice That Make Heavy Chain Antibodies - Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.06-16-2011
20090260093TRANSGENIC ANIMALS EXPRESSING CHIMERIC ANTIBODIES FOR USE IN PREPARING HUMAN ANTIBODIES - The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.10-15-2009
20090193530Animals, cells and methods for production of detectably-labeled antibodies - Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.07-30-2009
20090255002Transgenic Non-Human Animals For Producing Chimeric Antibodies - The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.10-08-2009
20100186100ANTIBODIES AND PEPTIDE ANTIGENS FOR PRODUCING ANTIBODIES HAVING A SELECTIVE BINDING SPECIFICITY TO BIOACTIVE INTACT PARATHYROID HORMONE (PTH) 1-84 - Peptide antigens corresponding to amino acid residues 2-12, 1-12, 2-15 and 1-15 of parathyroid hormone (PTH), antibodies having an affinity to such peptide antigens and methods of producing the same. Such antigens, antibodies and methods producing the same according to the present invention are useful in determining bioactive intact PTH levels in serum, plasma, and/or cell culture media. Such antibodies further possess a high degree of species cross-reactivity, but substantially mitigated cross-reactivity to non-whole PTH peptide fragments and little to no recognition of the first amino acid residue of PTH.07-22-2010
20110067122Expression of Xenogenous (Human) Immunoglobulins in cloned, transgenic ungulates - The present invention relates to the production of a transgenic ungulate which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.03-17-2011
20100306864POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.12-02-2010
20100306863SCREENING, THERAPY AND DIAGNOSIS - A TREM-1 ligand is identified. This allows various derivatives to be provided/identified that are capable of binding to the TREM-1 receptor. The TREM-1 ligand or the derivatives can be used in screening for drugs/drug candidates. Substances that block or reduce binding of the TREM-1 ligand/derivative to a TREM-1 receptor may be useful for treating sepsis, particularly sepsis of bacterial or fungal origin. Antibodies to the ligand may be useful in diagnosing sepsis, particularly sepsis of bacterial or fungal origin.12-02-2010
20110055938TRANSGENIC ANIMAL FOR PRODUCTION OF ANTIBODIES HAVING MINIMAL CDRS - A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.03-03-2011
20120151611 METHOD OF PRODUCING AN ANTIBODY USING A CANCER CELL - The present invention aims to provide a method for antibody preparation. The present invention is directed to a method for preparing an antibody-producing cell, which comprises the following steps: 06-14-2012
20110010781Method of Producing a Mouse Suitable for Engraftment, Differentiation and Proliferation of Heterologous Cells, Mouse Produced by This Method and Use of the Mouse - The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor γ-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.01-13-2011
20110138489TRANSGENIC ANIMALS EXPRESSING CHIMERIC ANTIBODIES FOR USE IN PREPARING HUMAN ANTIBODIES - The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.06-09-2011
20120047586POLYPEPTIDE HAVING ENHANCED EFFECTOR FUNCTION - Disclosed is a polypeptide having an enhanced effector function. Specifically disclosed are: a polypeptide having a modified Fc region; a nucleic acid encoding the polypeptide; a vector carrying the nucleic acid; a host cell or a host organism harboring the vector; a pharmaceutical composition comprising the polypeptide; a method for producing the polypeptide; a method for enhancing the effector function of an antibody; and a method for producing a cell capable of producing an antibody having a high effector function.02-23-2012
20120222140HUMAN ARTIFICIAL CHROMOSOME VECTOR - The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied.08-30-2012
20100205679Animals, cells and methods for production of detectably-labeled antibodies - Genetically-modified mammals and immune cells are provided which are capable of producing or secreting detectably-labeled immunoglobulin molecules as a result of genetic modifications of at least one immunoglobulin gene in the genome thereof, such that a fusion polynucleotide encoding a detectable protein or peptide and an immunoglobulin component molecule is present.08-12-2010
20120151610SOLUBLE "HEAVY-CHAIN ONLY" ANTIBODIES - The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework β-pleated sheet leading to increased net hydrophobicity within FR1 and an increased number of charged amino acids present in FR3. Also provided are VII domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.06-14-2012
20080235814Transgenic mammals having human Ig loci including plural VH and VK regions and antibodies produced therefrom - The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V09-25-2008
20130212719Humanized Rodents that Express Heavy Chain Containing VL Domains - Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.08-15-2013
800007000 The protein is isolated or extracted from milk 11
20090013419CATTLE BETA-CASEIN GENE TARGETING VECTOR USING HOMOLOGOUS RECOMBINATION - The present invention relates to a bovine beta-casein gene targeting vector comprising (1) a first region having a length of 5 to 12 kb which is homologous to the promoter and its flanking nucleic acid sequences of bovine beta-casein gene, and comprising exon 1, intron 1, and exon 2 of bovine beta-casein gene; (2) a region for cloning a nucleic acid coding for desired proteins; (3) a region for coding a positive selection marker; (4) a second region having a length of 2.8 to 3.5 kb which is homologous to the nucleic acid sequences of bovine beta-casein gene, and comprising exon 5, 6, 7 and 8, and intron 5, 6 and 7 of bovine beta-casein gene; wherein the nucleic acid segment corresponding to the first region is located upstream to the nucleic acid segment corresponding to the second region in the 5′-3′ arrangement of beta-casein gene. The present invention also relates to method producing the transgenic cattle which is bovine beta-casein gene-targeted with a gene coding a desired protein using the said vector and obtaining a large scale of a desired protein from the milk of the said transgenic cattle.01-08-2009
20100125918ENTEROVIRUS TYPE 71 PROTEIN AND METHOD FOR PRODUCTION - The invention provides a new type of a capsid protein VP1 of human enterovirus 71, named as MEL701-VP1 and functional/structural variants thereof, which is used for protection against enterovirus. The transgenic animal producing the protein, the composition comprising the protein and the method for production thereof are also provided.05-20-2010
20110209229Gene of porcine beta casein, a promoter of the same and the use thereof - The present invention provides a porcine beta-casein gene, a porcine beta-casein gene promoter, an expression vector comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates mammary gland-specific expression of the target protein and therefore can be useful for high-concentration production of beneficial proteins in milk.08-25-2011
20100162418RECOMBINANT PROTEIN S COMPOSITION - A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.06-24-2010
20100293623Rabbit nuclear cloning method and uses thereof - The invention concerns a method for producing non-human mammal embryos, in particular rabbit by nuclear cloning. The invention also concerns the mammals obtained and their uses.11-18-2010
20110072526PROCESS FOR PRODUCING EXOGENOUS PROTEIN IN THE MILK OF TRANSGENIC MAMMALS AND A PROCESS FOR PURIFYING PROTEINS THEREFROM - The invention relates to a method of producing a protein of interest, comprising making a non-human transgenic mammal that produces said protein in its milk, obtaining said milk from the non-human transgenic mammal and purifying said protein of interest from the milk. Transgenic bovine animals were generated, which are able to produce human growth hormone in mammary glands. The method involves cloning of a genetic construct comprising the hGH gene and beta casein promoter sequences conveniently in an expression vector. It also includes transfection procedures into fetal bovine somatic cells, generally fibroblasts, and the nuclear transfer into enucleated bovine oocytes, generating thus transgenic embryos. The method also includes other procedures to generate transgenic embryos for further expansion of the transgenic herd, such as the subcloning of transgenic female bovines, the superovulation of transgenic cows and their insemination with semen from a non-transgenic or a transgenic male bovine, and the superovulation of non-transgenic cows and their insemination with semen from a transgenic male bovine. Afterwards, transgenic embryos give rise to transgenic cattle that produce human growth hormone in huge amounts in their milk, from which the hormone is completely purified and analysed to fulfill all the requirements for the manufacture of a pure biopharmaceutical product.03-24-2011
20100205680MAMMARY GLAND- SPECIFIC HUMAN ERYTHEROPOIETIN EXPRESSION VECTOR, TRANSGENIC ANIMAL AND METHOD FOR PRODUCING HUMAN ERYTHROPOIETIN USING SAME - The present invention provides a mammary gland-specific human erythropoietin expression (hEPO) vector, transgenic animal and method for producing human erythropoietin using the same. The inventive hEPO-expressing transgenic animals express a mammary gland-specific EPO at an extremely higher concentration than the convention method. The hEPO produced from inventive transgenic animals shows better stability and superior physiological activity than those of the same kind of commerally available protein. Therefore, the inventive hEPO-expressing transgenic animals can be effectively used for production of EPO showing a superior physiological activity than the existing EPO.08-12-2010
20110239314Gene of porcine alpha-si casein, a promoter of the same and use thereof - The present invention relates to a porcine alpha-S1-casein gene, a porcine alpha-S1-casein gene promoter, an expression comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates the mammary gland-specific expression of the target protein. Accordingly, an animal transformed with the promoter secretes the target protein in milk at high concentration, and thus can be advantageously used for the production of useful proteins.09-29-2011
20110162094MODIFIED HUMAN FACTOR VII/VIIA AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - Modified factors VII/VIIa with a high stability, nucleic acids encoding such modified factors VII/VIIa, and methods of preparing the same.06-30-2011
20090187999Process for Producing Exogenous Protein in the Milk of Transgenic Mammals and a Process For Purifying Proteins Therefrom - The invention relates to a non-human transgenic mammal that is useful for the production of a protein of interest that may be toxic to the mammal. The mammal is characterized by the fact that it is transgenic for the production in its milk of an inactive form of the protein of interest, preferably recombinant human insulin. It is not possible to produce recombinant human insulin in transgenic mammals since this molecule has a certain degree of biological activity in the mammals and could be toxic to the mammal. Thus, the invention involves cloning a genetic construct comprising a sequence encoding a modified human insulin precursor under the control of a beta casein promoter in an expression vector. It also involves transfecting the expression plasmid into fetal bovine somatic cells, such as fibroblasts, and enucleating bovine oocytes by nuclear transfer to generate transgenic embryos. The invention gives rise to transgenic bovine that will be able to produce a modified human insulin precursor in their mammary glands. Afterwards, the milk of these transgenic mammals can be collected, the modified human insulin precursor can be converted in vitro into recombinant human insulin, and the recombinant human insulin can be purified to homogeneity as a pure biopharmaceutical product.07-23-2009
20080235815Administration of transposon-based vectors to reproductive organs - Methods and compositions for the administration of transposon-based vectors to the reproductive organs of animals and the creation of transgenic animals. Preferred methods involve administration of the transposon-based vectors to the lumen of the oviduct of an avian, expression of a vector derived transgene in the avian, and deposition of the resultant polypeptide in an egg. This invention allows for large amounts of protein to be deposited in the egg.09-25-2008

Patent applications in class METHOD OF USING A TRANSGENIC NONHUMAN ANIMAL TO MANUFACTURE A PROTEIN WHICH IS THEN TO BE ISOLATED OR EXTRACTED

Patent applications in all subclasses METHOD OF USING A TRANSGENIC NONHUMAN ANIMAL TO MANUFACTURE A PROTEIN WHICH IS THEN TO BE ISOLATED OR EXTRACTED